📄 medicine

Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography

This study demonstrates that combining serum CA19-9 levels with specific contrast-enhanced CT features, particularly the arterial phase tumor-to-pancreas enhancement ratio and pancreatic duct status, effectively differentiates pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma.

Original authors: Wenli Qiu, Jinghong Li, Chao Lu, Shuai Ren, Junxiong Zhao, Zhongqiu Wang

Published 2026-07-09

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Wenli Qiu, Jinghong Li, Chao Lu, Shuai Ren, Junxiong Zhao, Zhongqiu Wang

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the pancreas as a busy factory. Inside this factory, two very different types of "rogue workers" (cancer cells) can take over, causing the factory to malfunction. The problem is that these two troublemakers look and act so much alike that the factory managers (doctors) often mistake one for the other.

This study is like a detective guide helping managers tell these two rogues apart using a special "X-ray camera" (Contrast-Enhanced CT scan) and a blood test.

Here is the breakdown of the two suspects and how the study helps identify them:

The Two Suspects

The "Concrete Block" (PDAC): This is the most common type of pancreatic cancer. It's like a rogue worker who builds a massive, dense wall of concrete (scar tissue) around themselves. Because of this wall, they don't let much water (blood/contrast dye) flow through them. They also tend to clog the factory's main drainage pipes (the pancreatic duct).
The "Rare Imposter" (PNEC): This is a much rarer, but still dangerous, type of cancer. It comes from a different part of the factory (the hormone-producing cells). While it looks scary and aggressive, it doesn't build that same thick concrete wall. Because it's less dense, it lets more water flow through it.

The Problem: To the naked eye on a standard scan, both look like dark, shadowy blobs. Doctors often assume it's the "Concrete Block" (PDAC) because it's more common. But treating them is totally different! If you treat the "Rare Imposter" like a "Concrete Block," you might miss out on better treatments or surgery options.

The Detective Tools

The researchers looked at 64 cases of the "Concrete Block" and 17 cases of the "Rare Imposter" to see if their "X-ray camera" could spot the differences. They used three main clues:

1. The Blood Test Clue (CA19-9)

Think of the "Concrete Block" factory as a place that constantly leaks a specific type of smoke (a protein called CA19-9) into the air.

Finding: The "Concrete Block" group had very high levels of this smoke in their blood. The "Rare Imposter" group had much lower levels.
Simple Takeaway: If the blood smoke is low, it's a hint that it might be the rarer type.

2. The Drainage Pipe Clue (Pancreatic Duct)

The "Concrete Block" is a bully that grows along the factory's main drainage pipe, squeezing it shut and causing it to bulge (dilate).

Finding: The "Concrete Block" clogged the pipes in about 58% of cases. The "Rare Imposter" only clogged them in about 29% of cases.
Simple Takeaway: If the main pipe is wide open and not swollen, it leans toward the "Rare Imposter."

3. The "Water Flow" Clue (The CT Scan)

This is the most important part. The doctors injected a special dye into the patients' veins and took pictures at different speeds, like taking photos of a sponge soaking up water.

The "Concrete Block" (PDAC): Because of its dense concrete wall, it drinks up the dye very slowly. It stays dark in the early photos.
The "Rare Imposter" (PNEC): Because it has fewer walls and more open space, it soaks up the dye much faster and brighter in the early photos.

The "Golden Key":
The study found that the best way to tell them apart was to look at how bright the tumor was compared to the healthy factory floor immediately after the dye was injected (the "Arterial Phase").

They calculated a "Brightness Ratio" (Tumor Brightness ÷ Factory Floor Brightness).
The Result: This single number was a superstar detective. It was correct about 89% of the time. If the ratio was high, it was likely the "Rare Imposter." If it was low, it was likely the "Concrete Block."

What the Study Concludes

The researchers didn't invent a new machine or a new drug. Instead, they showed that if doctors combine three simple things:

Checking the "smoke" level in the blood (CA19-9).
Checking if the drainage pipe is clogged.
Looking at the "Brightness Ratio" on the early CT scan.

...they can much more accurately guess which type of cancer they are dealing with before surgery. This helps avoid misdiagnosis and ensures the patient gets the right treatment plan sooner.

In short: The "Rare Imposter" drinks the dye faster and clogs the pipes less than the "Concrete Block." By measuring how fast it drinks and checking the pipes, doctors can tell them apart with high accuracy.

Technical Summary: Differentiation of Pancreatic Neuroendocrine Carcinoma from Pancreatic Ductal Adenocarcinoma Using Contrast-Enhanced Computed Tomography

Problem Statement
Pancreatic neuroendocrine carcinoma (PNEC) and pancreatic ductal adenocarcinoma (PDAC) present a significant diagnostic challenge due to their highly analogous clinical manifestations and imaging characteristics. Despite sharing similar aggressive biological behaviors, these malignancies possess distinct histogenetic origins, treatment protocols, and prognostic outcomes. PDAC is the predominant exocrine malignancy with a poor prognosis, while PNEC, though rare, often responds differently to surgical resection and targeted therapies (e.g., sunitinib, everolimus). Preoperative misdiagnosis of PNEC as PDAC frequently leads to inappropriate treatment planning and delayed optimal intervention. While contrast-enhanced computed tomography (CE-CT) is the standard preoperative imaging modality, high-grade PNEC often mimics the hypovascular, ill-defined appearance of PDAC, resulting in a high rate of clinical misdiagnosis. This study addresses the need for objective, non-invasive imaging criteria to differentiate these two entities preoperatively.

Methodology
This retrospective observational study was conducted at the Affiliated Hospital of Nanjing University of Chinese Medicine and the Shenzhen Hospital of Guangzhou University of Chinese Medicine between February 2021 and December 2025. The study cohort included 81 patients with pathologically confirmed pancreatic malignancies: 64 with PDAC and 17 with PNEC.

Data Collection: Patients underwent multi-phase CE-CT (unenhanced, arterial, portal venous, and delayed phases) prior to any anti-tumor treatment.
Image Analysis: Two senior radiologists, blinded to clinical data, independently reviewed CT images. Qualitative features assessed included tumor location, margin definition, calcification, pancreatic duct dilatation, bile duct dilatation, parenchymal atrophy, and local invasion/metastasis.
Quantitative Analysis: Tumor attenuation values (Hounsfield Units, HU) were measured across all phases. Additionally, the tumor-to-pancreas enhancement ratio (tumor HU / normal pancreatic parenchyma HU) was calculated for the arterial, portal venous, and delayed phases.
Clinical Data: Serum biomarkers (CEA, CA125, CA153, CA19-9, ferritin, CRP) and clinical symptoms were extracted from electronic medical records.
Statistical Analysis: Differences between groups were analyzed using t-tests, Mann-Whitney U tests, or chi-square tests. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of significant variables, calculating the Area Under the Curve (AUC), sensitivity, and specificity.

Key Contributions and Results
The study identified specific serum and imaging markers that effectively distinguish PNEC from PDAC:

Serum Biomarkers: Serum CA19-9 levels were significantly lower in the PNEC group compared to the PDAC group ( $P < 0.001$ ). No significant differences were found in CEA, AFP, CA125, CA153, or ferritin levels.
Qualitative Imaging Features: Pancreatic duct dilatation was significantly more common in PDAC (57.81%) than in PNEC (29.41%) ( $P = 0.037$ ). Other qualitative features, including tumor location, margin definition, and calcification, showed no statistically significant differences.
Quantitative Imaging Features:
- CT Attenuation: PNEC demonstrated significantly higher attenuation values than PDAC in both the arterial phase ( $50.84 \pm 7.16$ HU vs. $40.33 \pm 8.67$ HU) and portal venous phase ( $56.97 \pm 6.21$ HU vs. $45.66 \pm 10.80$ HU) ( $P < 0.001$ ).
- Enhancement Ratios: The tumor-to-pancreas enhancement ratios were significantly higher for PNEC in the arterial and portal venous phases ( $P < 0.001$ ).
Diagnostic Performance: ROC analysis revealed that the arterial phase tumor-to-pancreas enhancement ratio provided the highest diagnostic accuracy, with an AUC of 0.935, sensitivity of 89.06%, and specificity of 88.24%. The portal venous phase ratio (AUC 0.891) and serum CA19-9 (AUC 0.887) also showed strong discriminatory power.

Significance and Claims
The authors claim that a combined assessment of serum CA19-9 levels and multi-phase CE-CT features offers a valuable approach for the preoperative differentiation of PNEC from PDAC. Specifically, the study highlights that:

Arterial Phase Enhancement: The arterial phase tumor-to-pancreas enhancement ratio is the most robust single indicator for differentiation, likely reflecting the richer microvascular bed of PNEC compared to the desmoplastic, hypovascular nature of PDAC.
Pancreatic Duct Status: The presence of pancreatic duct dilatation is a strong qualitative indicator favoring PDAC, attributed to the ductal origin and circumferential growth pattern of PDAC versus the expansive, non-invasive growth of PNEC.
Clinical Utility: These findings provide objective imaging evidence to reduce misdiagnosis rates. Accurate preoperative differentiation is critical for tailoring treatment strategies, as PNEC may be amenable to surgical resection even with limited metastases and targeted therapies, whereas PDAC management relies heavily on chemotherapy with limited surgical options for advanced stages.

The paper concludes that while histopathology remains the gold standard, integrating these specific CT parameters and CA19-9 levels can significantly improve diagnostic precision, thereby facilitating personalized therapeutic decision-making and potentially improving patient outcomes. The authors acknowledge limitations regarding the retrospective design, relatively small sample size for PNEC, and the lack of advanced post-processing techniques like spectral CT, suggesting that future large-scale prospective studies are necessary to validate these findings.